Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$11.51 USD
+0.52 (4.73%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $11.62 +0.11 (0.96%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
Cassava Sciences, Inc. [SAVA]
Reports for Purchase
Showing records 81 - 100 ( 126 total )
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 72122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 71122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 7122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 62122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 61122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Another of Cassava?s Roots Has Been Pulled: Maintain SELL: $8 Price Target
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 6122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Comprehensive Technical and Fundamental Analysis for SAVA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Phase 3 Enrollment Lagging; At Current Pace Could Take ~8 Years: Maintain Sell, $8 PT
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Momentum Regained With Uptick in Phase 3 Enrollment; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
SavaDx: Antibody or No Antibody, Unclear; Maintain SELL, $8 Price Target
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Comprehensive Technical and Fundamental Analysis for SAVA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Comprehensive Technical and Fundamental Analysis for SAVA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Cassava?s Roots are Being Investigated: Maintain SELL, $8 Price Target
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
This Cassava Won?t Take Root: Initiating Coverage of SAVA with a SELL, $8 Price Target
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Comprehensive Technical and Fundamental Analysis for SAVA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Showing It Can Do Big Things; Two Large Phase 3 Trials Initiated in 2021; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Comprehensive Technical and Fundamental Analysis for SAVA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Comprehensive Technical and Fundamental Analysis for SAVA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Comprehensive Technical and Fundamental Analysis for SAVA.
Provider: Stock Traders Daily
Analyst: Research Department